Protomer Technologies Inc. (“Protomer”), the biopharmaceutical company today announces the completion of an investment by the JDRF T1D Fund following an initial equity investment in Protomer led by Eli Lilly and Company.



Protomer is engineering next-generation protein therapeutics that can sense molecular activators in the body to automatically activate as needed. Using a proprietary peptide- and protein-engineering platform, Protomer is able to develop therapeutic proteins that can sense small molecule activators to achieve variable dosing and targeted delivery. Protomer’s chemical biology-based MEPS platform enables rapid turn-on and turn-off capability for automatic activity control of peptides and proteins, and enables the development of targeted therapies with dual homing to reduce off-target effects. www.protomer.com


Protomer Technologies Inc. Receives an Investment From JDRF T1D Fund Following a Lead Equity Investment by Lilly

Description

Company Information

Protomer Technologies Inc. Receives an Investment From JDRF T1D Fund Following a Lead Equity Investment by Lilly

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Company Information